$10.12
2.64% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$10.12
+0.98 10.72% 1M
-0.48 4.53% 6M
-2.33 18.71% YTD
-1.45 12.53% 1Y
-1.01 9.07% 3Y
-6.06 37.45% 5Y
-45.24 81.72% 10Y
-7.77 43.43% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.26 2.64%

Key metrics

Basic
Market capitalization
$11.0b
Enterprise Value
$24.3b
Net debt
$13.3b
Cash
$849.5m
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
negative | 4.4
P/S
0.8 | 0.8
EV/Sales
1.7 | 1.7
EV/FCF
13.2
P/B
0.7
Dividends
DPS
$0.48
Yield 1Y | 5Y
4.9% | 2.7%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
-90.6% | 117.1%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$14.3b | $14.1b
EBITDA
$4.4b | $4.1b
EBIT
$1.5b | $3.7b
Net Income
$-3.8b | $2.7b
Free Cash Flow
$1.9b
Growth (TTM | estimate)
Revenue
-6.7% | -4.5%
EBITDA
4.9% | -11.7%
EBIT
2.7% | 110.7%
Net Income
-6,656.0% | 522.1%
Free Cash Flow
-7.4%
Margin (TTM | estimate)
Gross
40.7%
EBITDA
30.6% | 29.3%
EBIT
10.6%
Net
-26.5% | 19.0%
Free Cash Flow
12.9%
Financial Health
Equity Ratio
44.9%
Return on Equity
-3.4%
ROCE
4.7%
ROIC
4.3%
Debt/Equity
0.9
More
EPS
$-3.2
FCF per Share
$1.6
Short interest
3.7%
Employees
33k
Rev per Employee
$450.0k
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Viatris forecast:

2x Buy
13%
8x Hold
53%
5x Sell
33%

Analyst Opinions

15 Analysts have issued a Viatris forecast:

Buy
13%
Hold
53%
Sell
33%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14,330 14,330
7% 7%
100%
- Direct Costs 8,500 8,500
2% 2%
59%
5,831 5,831
12% 12%
41%
- Selling and Administrative Expenses 3,480 3,480
20% 20%
24%
- Research and Development Expense 827 827
1% 1%
6%
4,391 4,391
5% 5%
31%
- Depreciation and Amortization 2,867 2,867
6% 6%
20%
EBIT (Operating Income) EBIT 1,524 1,524
3% 3%
11%
Net Profit -3,790 -3,790
6,656% 6,656%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Neutral
PRNewsWire
one day ago
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH , Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Admini...
Neutral
Seeking Alpha
5 days ago
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Theodora Mistras - Chief Financial Officer William Szablewski - Former Head of Capital Markets Conference Call Participants Ashwani Verma - UBS Investment Bank, Research D...
Positive
Reuters
6 days ago
Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 33,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today